Graduate School of Engineering Science

GOSSELIES, Belgium and NANTES, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in autoimmune and inflammatory disease drug development. The SAB will work closely with the AbolerIS team to advance its lead program, ABO21009, a humanized anti-CD45RC monoclonal antibody, through Phase 1 for rheumatoid arthritis (RA). Pending clinical proof-of-concept in RA, the Company intends to broaden its development into other autoimmune diseases. Durable, long-term remission remains elusive in many autoimmune diseases such as RA. The SAB will also assist the AbolerIS management with the planned development of additional indications for ABO21009 and the expansion and subsequent development of the Company's portfolio. The members of our Scientific Advisory Board combine deep preclinical, translational and clinical expertise in a broad range of autoimmune diseases. Ronald Van Brempt, MD, Chief Medical Officer of AbolerIS, commented: "We are privileged to work with Dirk, Mary, Georg, Rene, Michel, Edouard, and Ignacio, to bring a novel therapy like ABO21009 to patients suffering from the debilitating effects of autoimmune disease. These recognized leaders bring a great understanding of inflammatory and autoimmune diseases, as well as deep expertise in advancing scientific breakthroughs towards the clinic. We look forward to their contributions as we advance ABO21009 in the clinic for RA and additional indications like Sjögren`s Disease, Graft-versus-Host Disease, Inflammatory Bowel Disease, and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy as we continue to grow our company." Members of the AbolerIS Scientific Advisory Board are listed below. Complete biographies are available on the AbolerIS website. Dirk Elewaut, MD, PhD, Chairman of the Scientific Advisory Board: Full Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology and Immunology at Ghent University Hospital, Ghent, Belgium VIB Group leader, VIB-UGent Center for Inflammation Research, Ghent, Belgium "I have dedicated my career to advancing research in immunology and inflammatory disease, and the potential of ABO21009 is very promising. I am honored to lead the world-class leaders on the SAB with the goal to advance AbolerIS' research toward patients in need," commented Dr. Elewaut. Mary Crow, MD, PhD Physician-in-Chief Emeritus at Hospital for Special Surgery, Professor of Medicine at Weill Cornell Medical College, and Professor of Immunology in its Graduate School of Medical Sciences, New York, USA Senior Scientist, Co-Director of the Mary Kirkland Center for Lupus Research, and Director of the Autoimmunity and Inflammation Program at Hospital for Special Surgery's Research Institute (holder of the Benjamin M. Rosen Chair in Immunology and Inflammation Research), New York, USA Georg Schett, MD, PhD Vice President Research, Chair of Internal Medicine III - Rheumatology and Immunology, Uniklinikum Erlangen - Friedrich Alexander University, Erlangen-Nurnberg, Germany Rene Toes, PhD Full Professor of Experimental Rheumatology, Leiden University Medical Center (LUMC), Leiden, the Netherlands Head of the Laboratory of Dept. of Rheumatology, LUMC, Leiden, the Netherlands Michel Goldman, MD, PhD Founder and the President of the I³h Institute and Professor of Immunology and Pharmacotherapy at the Université libre de Bruxelles (ULB) Executive Director Emeritus of the Innovative Medicines Initiative (IMI) from 2009 to 2014 Head Emeritus of the Department of Immunology at Erasme Hospital and Director Emeritus of the Institute for Medical Immunology (ULB) Edouard Louis, MD, PhD Professor of Gastroenterology and Head of the Gastroenterology department at Liège University hospital. Liege, Belgium Dean of the faculty of Medicine at Liège University, Liege, Belgium Ignacio Anegon, MD, PhD Director of Research (DRE) at INSERM-CRTI Director Transgenesis Rat ImmunoPhenomic facility, Co-Founder of AbolerIS Pharma About ABO21009 ABO21009 is the Company's lead monoclonal antibody program stemming from its novel immunomodulatory approach to treating autoimmune and inflammatory diseases. ABO21009 is effective through a multi-pronged mechanism of action, selectively depleting CD45RC-positive cells that are actively sustaining the autoimmune response in Rheumatoid Arthritis. These CD45RC-positive cells are present in the T-, B-, and NK-cell compartments of the adaptive immune system. By selectively depleting these cells, the cells driving the autoimmune disease are taken out of the immune cell population. ABO21009 also spares regulatory T-cells, which can unleash their full potential and suppress ongoing and future autoimmune activity in the adaptive immune system. Treatment with ABO21009 may enable a long-lasting and durable remission in RA, which will improve the patient experience and lessen the burden of side effects from currently available therapeutic options. About AbolerIS Pharma AbolerIS Pharma is a clinical-stage biopharmaceutical company committed to improving the lives of patients suffering from autoimmune and inflammatory diseases. The Company is advancing potentially best-in-class and first-in-class immunomodulatory antibodies that target CD45RC, a key regulator of the immune system. AbolerIS' lead program, ABO21009, is designed to demonstrate broad efficacy in multiple autoimmune and inflammatory disorders with large unmet medical needs including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and organ transplantation. At AbolerIS, we envision a future where patients can enjoy long-term remission and improved quality of life through therapies that are effective and safe. The Company is based in Gosselies, Belgium and Nantes, France, and is backed by a syndicate of experienced investors, which includes Criteria Bio Ventures, Sound Bioventures, Newton Biocapital, WE, Sambrinvest, SFPIM and Sham Innovation Santé. For more information, please visit to learn more about our transformative approach to immunotherapies and follow us on LinkedIn. Media & Investor Contact Amy Conrad Juniper Point [email protected] SOURCE AbolerIS Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

HYOGO, Japan I October 31, 2024 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced the initiation of the first patient dosing in Japan in the Phase I clinical trial of JR-441, an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo syndrome type A). JR-441 is a proprietary recombinant heparan N-sulfatase capable of crossing the blood-brain barrier (BBB). MPS IIIA is a rare genetic disorder characterized by severe central nervous system (CNS) symptoms, for which there is currently no approved treatment. Preclinical studies have demonstrated the potential of JR-441 to address CNS-related symptoms associated with MPS IIIA. This open-label, multicenter, single-arm study aims to assess the safety profile, biological effect, and pharmacokinetic profile of JR-441 in patients aged 1 to under 18 years with MPS IIIA. “MPS IIIA has been one of the most significant challenges in the treatment of CNS symptoms,” said Dr. Kimitoshi Nakamura, Professor of Pediatrics at the Graduate School of Medical Sciences, Kumamoto University, and the Medical Expert of the study. “This novel therapeutic approach represents a new era for managing the condition. We have been eagerly awaiting the opportunity to offer this treatment, and I am hopeful that its effectiveness will be confirmed in the clinical setting, ultimately improving the daily lives of both patients and their families.” JR-441 received Orphan Drug Designation from both the European Commission (EC) and the U.S. Food and Drug Administration (FDA), with a Phase I/II trial underway in Germany, which began in 2023 (JR-441-101, NCT06095388 ). For more details on the Japanese Phase I trial, visit the Clinical Research Submission and Disclosure System (JR-441-JP11, jRCT2071240053 ). About Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) Mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A, is an autosomal recessive disease caused by pathogenic mutations in the SGSH gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. The accumulation of heparan sulfate in several types of cells of the body, especially in the central nervous system in the brain, results in severe neurological deterioration, cognitive impairment, mild somatic involvement, and shortened lifespan. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/ . SOURCE: JCR Pharmaceuticals

A research team has found a de-icing mixture with high effectiveness and low environmental impact after using machine learning to analyze ice melting mechanisms of aqueous solutions of 21 salts and 16 organic solvents. The dangers of frozen roads, airplane engines, and runways are well known, but the use of commercial products often means short-term safety over long-term environmental degradation. Seeking a better product, Osaka Metropolitan University researchers have developed a deicing mixture offering higher performance than deicers on the market while also having less impact on the environment. The team, made up of graduate student Kai Ito, Assistant Professor Arisa Fukatsu, Associate Professor Kenji Okada, and Professor Masahide Takahashi of the Graduate School of Engineering, used machine learning to analyze ice melting mechanisms of aqueous solutions of 21 salts and 16 organic solvents. The group then conducted experiments to find that a mixture of propylene glycol and aqueous sodium formate solution showed the best ice penetration capacity. Because of the mixture's effectiveness, less of the substance needs to be used, thereby also lessening the environmental impact. It is also not corrosive, preventing damage, for example, when used for airport runways. "We are proposing an effective and environmentally friendly deicer that combines the advantages of salts and organic solvents," exclaimed Dr. Fukatsu. The results of this research, published in Scientific Reports on June 7, 2024, also provide new insights into the ice melting process. "The development of highly efficient deicers is expected to make deicing and anti-icing operations easier," Professor Takahashi added. "This will also lessen the environmental impact by reducing the amount of deicer used."